Currently, extensive research is investigating strategies to mitigate the progression of liver fibrosis [26–28], including the use of receptor antagonists or the reduction of IL-1β and TNF-α levels in vivo [29–31]. This evidence concerns the gene TNF and Hepatic fibrosis.